DK2942051T3 - Fast farmaceutisk doseringsform der omfatter en fast dispersion af hiv-protease-inhibitor - Google Patents
Fast farmaceutisk doseringsform der omfatter en fast dispersion af hiv-protease-inhibitor Download PDFInfo
- Publication number
- DK2942051T3 DK2942051T3 DK15169378.5T DK15169378T DK2942051T3 DK 2942051 T3 DK2942051 T3 DK 2942051T3 DK 15169378 T DK15169378 T DK 15169378T DK 2942051 T3 DK2942051 T3 DK 2942051T3
- Authority
- DK
- Denmark
- Prior art keywords
- dosage form
- weight
- pharmaceutical dosage
- solid
- amino
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (10)
1. Fast farmaceutisk doseringsform til anvendelse ved behandling af HIV, hvilken doseringsform omfatter en fast dispersion, som omfatter mindst en HIV-protease-inhibitor i mindst en farmaceutisk acceptabel vandopløselig polymer og mindst et farmaceutisk acceptabelt ikke-ionisk overfladeaktivt middel, hvor den nævnte HIV-protease-inhibitor omfatter lopinavir, og hvor det farmaceutisk acceptable ikke-ioniske overfladeaktive middel omfatter et overfladeaktivt middel, der har en HLB-værdi på fra 4 til 10.
2. Fast farmaceutisk doseringsform til anvendelsen ifølge krav 1, hvor den faste dispersion er en glasagtig opløsning eller fast opløsning af den mindst ene HIV-protease-inhibitor.
3. Fast farmaceutisk doseringsform til anvendelse ifølge krav 1 eller krav 2, hvor det overfladeaktive middel, der har en HLB-værdi på fra 4 til 10, har en HLB-værdi på fra 7 til 9.
4. Fast farmaceutisk doseringsform til anvendelse ifølge krav 1 eller krav 2, hvor det overfladeaktive middel, der har en HLB-værdi på fra 4 til 10, er en sorbitanfedtsyremonoester.
5. Fast farmaceutisk doseringsform til anvendelsen ifølge krav 4, hvor sorbitanfedtsyremonoesteren er valgt blandt sorbitanmonolaurat, sorbitanmonooleat, sorbitanmonopalmitat og sorbitanstearat.
6. Fast farmaceutisk doseringsform til anvendelse ifølge et hvilket som helst af de foregående krav, hvor den farmaceutisk acceptable vandopløselige polymer har en Tg på mindst 50 °C.
7. Fast farmaceutisk doseringsform til anvendelsen ifølge krav 6, hvor den farmaceutisk acceptable vandopløselige polymer har en Tg på fra 80 til 180 °C.
8. Fast farmaceutisk doseringsform til anvendelse ifølge et hvilket som helst af de foregående krav, hvor den farmaceutisk acceptable vandopløselige polymer omfatter en homopolymer eller copolymer af N-vinylpyrrolidon.
9. Fast farmaceutisk doseringsform til anvendelse ifølge krav 8, hvor den farmaceutisk acceptable vandopløselige polymer omfatter en copolymer af N-vinylpyrrolidon og vinylacetat.
10. Fast farmaceutisk doseringsform til anvendelse ifølge et hvilket som helst af de foregående krav, hvilken doseringsform indeholder mindst ét additiv der er udvalgt blandt strømningsregulatorer, smøremidler, fyldmidler og sprængmidler.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/650,178 US20050048112A1 (en) | 2003-08-28 | 2003-08-28 | Solid pharmaceutical dosage form |
EP10181264.2A EP2258345B1 (en) | 2003-08-28 | 2004-08-23 | Solid pharmaceutical dosage form comprising an HIV protease inhibitor solid dispersion |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2942051T3 true DK2942051T3 (da) | 2018-05-07 |
Family
ID=34217089
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10181264.2T DK2258345T3 (da) | 2003-08-28 | 2004-08-23 | Fast farmaceutisk doseringsform omfattende en fast dispersion af en HIV-proteaseinhibitor |
DK10181250.1T DK2258344T3 (da) | 2003-08-28 | 2004-08-23 | Fast farmaceutisk doseringsform omfattende en fast dispersion af ritonavir og lopinavir |
DK04816820.7T DK1663183T3 (da) | 2003-08-28 | 2004-08-23 | Fast farmaceutisk doseringsform omfattende ritonavir |
DK10181268.3T DK2258346T3 (da) | 2003-08-28 | 2004-08-23 | Fast farmaceutisk doseringsform omfattende en fast dispersion af en hiv-proteaseinhibitor |
DK15169378.5T DK2942051T3 (da) | 2003-08-28 | 2004-08-23 | Fast farmaceutisk doseringsform der omfatter en fast dispersion af hiv-protease-inhibitor |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10181264.2T DK2258345T3 (da) | 2003-08-28 | 2004-08-23 | Fast farmaceutisk doseringsform omfattende en fast dispersion af en HIV-proteaseinhibitor |
DK10181250.1T DK2258344T3 (da) | 2003-08-28 | 2004-08-23 | Fast farmaceutisk doseringsform omfattende en fast dispersion af ritonavir og lopinavir |
DK04816820.7T DK1663183T3 (da) | 2003-08-28 | 2004-08-23 | Fast farmaceutisk doseringsform omfattende ritonavir |
DK10181268.3T DK2258346T3 (da) | 2003-08-28 | 2004-08-23 | Fast farmaceutisk doseringsform omfattende en fast dispersion af en hiv-proteaseinhibitor |
Country Status (31)
Country | Link |
---|---|
US (1) | US20050048112A1 (da) |
EP (6) | EP2258345B1 (da) |
JP (6) | JP4815348B2 (da) |
KR (5) | KR20150044031A (da) |
CN (5) | CN105106104A (da) |
AT (1) | ATE516017T1 (da) |
AU (3) | AU2004283087C1 (da) |
CA (2) | CA2689639C (da) |
CR (3) | CR8256A (da) |
CY (5) | CY1111981T1 (da) |
DK (5) | DK2258345T3 (da) |
EA (4) | EA033224B1 (da) |
EC (1) | ECSP066397A (da) |
ES (5) | ES2608720T3 (da) |
HK (4) | HK1094766A1 (da) |
HR (1) | HRP20110555T1 (da) |
HU (3) | HUE031153T2 (da) |
IL (3) | IL173939A (da) |
ME (2) | MEP17608A (da) |
MX (2) | MXPA06002346A (da) |
NO (3) | NO330282B1 (da) |
NZ (2) | NZ545499A (da) |
PL (5) | PL2258344T3 (da) |
PT (5) | PT2258346T (da) |
RS (2) | RS57663B1 (da) |
SG (3) | SG179401A1 (da) |
SI (5) | SI1663183T1 (da) |
TW (1) | TWI342221B (da) |
UA (1) | UA85564C2 (da) |
WO (1) | WO2005039551A2 (da) |
ZA (3) | ZA200801362B (da) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5767429B2 (ja) * | 1999-11-12 | 2015-08-19 | アッヴィ・インコーポレイテッド | 固体分散剤中の結晶化阻害剤 |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
US8377952B2 (en) * | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
US20050048112A1 (en) | 2003-08-28 | 2005-03-03 | Jorg Breitenbach | Solid pharmaceutical dosage form |
AU2012202831B2 (en) * | 2005-02-23 | 2015-01-22 | Abbvie Inc. | A solid pharmaceutical dosage formulation |
KR20070025070A (ko) * | 2005-08-31 | 2007-03-08 | 주식회사 대웅제약 | 시부트라민 및 계면활성제를 함유하는 고체분산체 및 그의제조방법 |
PL1962808T3 (pl) * | 2005-12-14 | 2011-03-31 | Hoffmann La Roche | Preparat proleku przeciw HCV |
SI2051703T1 (sl) * | 2005-12-14 | 2011-01-31 | Cipla Ltd | Farmacevtski sestavki, ki vsebujejo inhibitorje nukleotidne in nukleozidne reverzne transkriptaze (kot tenofovir in lamivudin) v različnih delih dozirne oblike |
WO2007087188A2 (en) * | 2006-01-20 | 2007-08-02 | Merck & Co., Inc. | Taste-masked tablets and granules |
EP1832281A1 (en) * | 2006-03-10 | 2007-09-12 | Abbott GmbH & Co. KG | Process for producing a solid dispersion of an active ingredient |
EP1880715A1 (en) | 2006-07-19 | 2008-01-23 | Abbott GmbH & Co. KG | Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same |
UY30535A1 (es) * | 2006-08-10 | 2008-03-31 | Cipla Ltd | Composicion comprendiendo farmacos antirretrovirales y al menos un polimero insoluble en agua, proceso de preparacion y aplicaciones. |
WO2008067164A2 (en) | 2006-11-15 | 2008-06-05 | Abbott Laboratories | Solid pharmaceutical dosage formulations |
LT2487166T (lt) | 2007-02-23 | 2016-11-10 | Gilead Sciences, Inc. | Terapinių agentų farmakokinetinių savybių moduliatoriai |
PA8809601A1 (es) * | 2007-12-24 | 2009-07-23 | Cipla Ltd | Combinación anti-retroviral |
EP2257279B1 (en) * | 2008-02-28 | 2016-08-17 | AbbVie Inc. | Preparation of tablets |
WO2009153654A1 (en) * | 2008-06-17 | 2009-12-23 | Aurobindo Pharma Limited | Solid dosage forms of antiretrovirals |
EA020783B1 (ru) * | 2008-10-07 | 2015-01-30 | Астразенека Юк Лимитед | Фармацевтическая композиция, содержащая 4-[3-(4-циклопропанкарбонилпиперазин-1-карбонил)-4-фторбензил]-2н-фталазин-1-он и коповидон |
WO2010070611A1 (en) | 2008-12-18 | 2010-06-24 | Ranbaxy Laboratories Limited | Atazanavir formulations |
TW201043269A (en) * | 2009-04-14 | 2010-12-16 | Bristol Myers Squibb Co | Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
TWI540132B (zh) | 2009-06-08 | 2016-07-01 | 亞培公司 | Bcl-2族群抑制劑之口服醫藥劑型 |
WO2011013110A1 (en) | 2009-07-31 | 2011-02-03 | Ranbaxy Laboratories Limited | Unit dosage forms of hiv protease inhibitors |
EP2279728A1 (en) | 2009-07-31 | 2011-02-02 | Ranbaxy Laboratories Limited | Solid dosage forms of HIV protease inhibitors |
HRP20220796T1 (hr) | 2010-10-01 | 2022-10-14 | ModernaTX, Inc. | Ribonukleinske kiseline koje sadrže n1-metil-pseudouracil i njihove uporabe |
UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
CA2829186A1 (en) * | 2011-03-07 | 2012-09-13 | Bandi Parthasaradhi Reddy | Amorphous form of lopinavir and ritonavir mixture |
EP2714683A4 (en) | 2011-05-27 | 2014-11-05 | Hetero Research Foundation | RITONAVIR AMORPH CO-PRECIPITATION |
IN2014CN00827A (da) * | 2011-08-16 | 2015-04-03 | Merck Sharp & Dohme | |
EP2564832A1 (en) | 2011-08-29 | 2013-03-06 | Hexal AG | Solid dosage form of HIV protease inhibitors |
KR101794032B1 (ko) * | 2011-09-21 | 2017-11-07 | (주)바이오시네틱스 | 나노입자 제조방법 |
US9370578B2 (en) | 2012-03-07 | 2016-06-21 | Ratiopharm Gmbh | Dosage form comprising lopinavir and ritonavir |
HUE027829T2 (en) | 2012-03-07 | 2016-11-28 | Ratiopharm Gmbh | Dosage forms containing non-crystalline lopinavir and crystalline ritonavir |
CN103655571B (zh) * | 2012-09-11 | 2016-04-20 | 上海星泰医药科技有限公司 | 一种洛匹那韦和利托那韦复方高均匀度纳米共分散体及其制备方法 |
CN104684545B (zh) | 2012-09-27 | 2018-04-03 | 巴斯夫欧洲公司 | 包含至少一种水溶性维生素e衍生物和至少一种亲水聚合物的储存稳定的无粉尘均质颗粒状配制剂 |
US9744240B2 (en) | 2012-09-27 | 2017-08-29 | Basf Se | Storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin E-derivative and at least one hydrophilic polymer |
US9789063B2 (en) | 2012-09-27 | 2017-10-17 | Basf Se | Storage-stable dust-free homogeneous particulate formulation |
WO2014048782A1 (en) | 2012-09-27 | 2014-04-03 | Basf Se | A storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin e-derivative and at least one hydrophilic polymer |
RU2505286C1 (ru) | 2012-12-29 | 2014-01-27 | Открытое Акционерное Общество "Фармасинтез" | Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения |
RU2543322C1 (ru) * | 2013-09-19 | 2015-02-27 | Открытое Акционерное Общество "Фармасинтез" | Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения |
RU2619840C1 (ru) * | 2016-09-21 | 2017-05-18 | Общество с ограниченной ответственностью "Изварино Фарма" | Фармацевтическая композиция для лечения ВИЧ-инфекции |
RU2659693C1 (ru) * | 2017-06-30 | 2018-07-03 | Общество с ограниченной ответственностью "Изварино Фарма" | Фармацевтическая композиция, обладающая активностью против ВИЧ-инфекции |
US20190038754A1 (en) * | 2017-08-07 | 2019-02-07 | SE Tylose, USA, Inc. | Pharmaceutical composition in solid extruded form |
US20210361639A1 (en) * | 2018-03-02 | 2021-11-25 | The University Of Liverpool | Solid compositions of actives, processes for preparing same and uses of such solid compositions |
CN108186578A (zh) * | 2018-03-27 | 2018-06-22 | 聊城大学 | 一种利托那韦固体分散体的制备方法 |
EP3569225A1 (en) | 2018-05-18 | 2019-11-20 | Pharmaceutical Oriented Services Ltd | Solid dispersion containing ritonavir |
TWI799599B (zh) * | 2019-06-06 | 2023-04-21 | 華納國際生物科技股份有限公司 | 醫藥或保健品自乳化固體分散組成物 |
CN114146061B (zh) * | 2020-09-07 | 2023-06-30 | 歌礼生物科技(杭州)有限公司 | 包含固体分散体的蛋白酶抑制剂增效组合物及其制备方法 |
CN116887866A (zh) | 2020-12-03 | 2023-10-13 | 巴特尔纪念研究院 | 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法 |
WO2022216977A1 (en) | 2021-04-07 | 2022-10-13 | Batelle Memorial Institute | Rapid design, build, test, and learn technologies for identifying and using non-viral carriers |
CN113318076B (zh) * | 2021-06-02 | 2022-09-23 | 聊城大学 | 一种兼具增溶及抑晶效果的利托那韦固体分散体及其制备方法 |
CN114557967B (zh) * | 2022-03-17 | 2023-06-02 | 乐普制药科技有限公司 | 一种利托那韦固体分散体的制备方法 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2525108B1 (fr) | 1982-04-19 | 1989-05-12 | Elan Corp Ltd | Medicaments a haut degre de solubilite et procede pour leur obtention |
DE3830353A1 (de) | 1988-09-07 | 1990-03-15 | Basf Ag | Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen |
US5354866A (en) * | 1989-05-23 | 1994-10-11 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US5552558A (en) * | 1989-05-23 | 1996-09-03 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US5542206A (en) | 1994-10-11 | 1996-08-06 | Lisch; Albert | Lure and tackle stacking container |
US5914332A (en) * | 1995-12-13 | 1999-06-22 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US6232333B1 (en) * | 1996-11-21 | 2001-05-15 | Abbott Laboratories | Pharmaceutical composition |
US6027747A (en) * | 1997-11-11 | 2000-02-22 | Terracol; Didier | Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions |
DE19841244A1 (de) * | 1998-09-09 | 2000-03-16 | Knoll Ag | Verfahren und Vorrichtung zum Herstellen von Tabletten |
ATE400252T1 (de) | 1999-02-10 | 2008-07-15 | Pfizer Prod Inc | Pharmazeutische feste dispersionen |
US20030104048A1 (en) * | 1999-02-26 | 2003-06-05 | Lipocine, Inc. | Pharmaceutical dosage forms for highly hydrophilic materials |
DE19913606A1 (de) | 1999-03-25 | 2000-09-28 | Basf Ag | Pulverförmige Solubilisationshilfsstoffe für feste pharmazeutische Darreichungsformen |
DE19913692A1 (de) * | 1999-03-25 | 2000-09-28 | Basf Ag | Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen |
TR200103488T2 (tr) | 1999-06-04 | 2002-04-22 | Abbott Laboratories | Geliştirilmiş farmasötik formülasyonlar. |
JP5767429B2 (ja) * | 1999-11-12 | 2015-08-19 | アッヴィ・インコーポレイテッド | 固体分散剤中の結晶化阻害剤 |
JP4815085B2 (ja) | 1999-11-12 | 2011-11-16 | アボット・ラボラトリーズ | 固体分散体医薬製剤 |
EP1401503B1 (en) | 2001-06-22 | 2007-05-09 | Pfizer Products Inc. | Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug and a solubility-enhancing polymer |
EP1469832B2 (en) * | 2002-02-01 | 2016-10-26 | Bend Research, Inc. | Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials |
DE10213242A1 (de) * | 2002-03-25 | 2003-10-16 | Abbott Gmbh & Co Kg | Testsystem zur Evaluierung der Kompatibilität biologisch aktiver Substanzen mit Copolymeren |
DE10247037A1 (de) * | 2002-10-09 | 2004-04-22 | Abbott Gmbh & Co. Kg | Herstellung von festen Dosierungsformen unter Verwendung eines vernetzten nichtthermoplastischen Trägers |
US20050048112A1 (en) | 2003-08-28 | 2005-03-03 | Jorg Breitenbach | Solid pharmaceutical dosage form |
US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
WO2008067164A2 (en) | 2006-11-15 | 2008-06-05 | Abbott Laboratories | Solid pharmaceutical dosage formulations |
-
2003
- 2003-08-28 US US10/650,178 patent/US20050048112A1/en not_active Abandoned
-
2004
- 2004-08-23 EP EP10181264.2A patent/EP2258345B1/en not_active Revoked
- 2004-08-23 KR KR20157009392A patent/KR20150044031A/ko not_active Application Discontinuation
- 2004-08-23 NZ NZ545499A patent/NZ545499A/en not_active IP Right Cessation
- 2004-08-23 WO PCT/US2004/027401 patent/WO2005039551A2/en active Application Filing
- 2004-08-23 AU AU2004283087A patent/AU2004283087C1/en not_active Revoked
- 2004-08-23 PL PL10181250T patent/PL2258344T3/pl unknown
- 2004-08-23 CA CA2689639A patent/CA2689639C/en not_active Expired - Fee Related
- 2004-08-23 DK DK10181264.2T patent/DK2258345T3/da active
- 2004-08-23 EP EP15169378.5A patent/EP2942051B1/en not_active Revoked
- 2004-08-23 PL PL15169378T patent/PL2942051T3/pl unknown
- 2004-08-23 CN CN201510531654.1A patent/CN105106104A/zh active Pending
- 2004-08-23 PT PT101812683T patent/PT2258346T/pt unknown
- 2004-08-23 KR KR1020067004057A patent/KR101132602B1/ko active IP Right Grant
- 2004-08-23 EA EA201301045A patent/EA033224B1/ru not_active IP Right Cessation
- 2004-08-23 SI SI200431719T patent/SI1663183T1/sl unknown
- 2004-08-23 CA CA2536638A patent/CA2536638C/en not_active Expired - Fee Related
- 2004-08-23 ZA ZA200801362A patent/ZA200801362B/en unknown
- 2004-08-23 DK DK10181250.1T patent/DK2258344T3/da active
- 2004-08-23 EP EP10181268.3A patent/EP2258346B1/en not_active Revoked
- 2004-08-23 JP JP2006524782A patent/JP4815348B2/ja not_active Expired - Lifetime
- 2004-08-23 PL PL10181268T patent/PL2258346T3/pl unknown
- 2004-08-23 SI SI200432367A patent/SI2258345T1/sl unknown
- 2004-08-23 NZ NZ579622A patent/NZ579622A/en not_active IP Right Cessation
- 2004-08-23 EA EA201890737A patent/EA201890737A3/ru unknown
- 2004-08-23 CN CN2012102597395A patent/CN102764244A/zh active Pending
- 2004-08-23 EA EA200900292A patent/EA020992B1/ru not_active IP Right Cessation
- 2004-08-23 RS YU20060140A patent/RS57663B1/sr unknown
- 2004-08-23 PT PT101812642T patent/PT2258345T/pt unknown
- 2004-08-23 RS RS20181262A patent/RS59969B1/sr unknown
- 2004-08-23 CN CN2010102227346A patent/CN101919858B/zh not_active Ceased
- 2004-08-23 HU HUE10181264A patent/HUE031153T2/en unknown
- 2004-08-23 CN CN201210259721.5A patent/CN102772380B/zh not_active Ceased
- 2004-08-23 SI SI200432438T patent/SI2942051T1/en unknown
- 2004-08-23 PL PL04816820T patent/PL1663183T3/pl unknown
- 2004-08-23 KR KR1020127011945A patent/KR101457967B1/ko active IP Right Grant
- 2004-08-23 SG SG2012008959A patent/SG179401A1/en unknown
- 2004-08-23 HU HUE10181268A patent/HUE035985T2/hu unknown
- 2004-08-23 AT AT04816820T patent/ATE516017T1/de active
- 2004-08-23 ES ES10181264.2T patent/ES2608720T3/es not_active Expired - Lifetime
- 2004-08-23 MX MXPA06002346A patent/MXPA06002346A/es active IP Right Grant
- 2004-08-23 EP EP10181250A patent/EP2258344B1/en not_active Revoked
- 2004-08-23 KR KR1020117025014A patent/KR101281994B1/ko active IP Right Grant
- 2004-08-23 ES ES15169378.5T patent/ES2666390T3/es not_active Expired - Lifetime
- 2004-08-23 SI SI200431996T patent/SI2258344T1/sl unknown
- 2004-08-23 ME MEP-176/08A patent/MEP17608A/xx unknown
- 2004-08-23 ES ES10181250T patent/ES2399810T3/es not_active Expired - Lifetime
- 2004-08-23 ES ES04816820T patent/ES2367173T3/es not_active Expired - Lifetime
- 2004-08-23 SG SG200805563-4A patent/SG145690A1/en unknown
- 2004-08-23 PT PT151693785T patent/PT2942051T/pt unknown
- 2004-08-23 DK DK04816820.7T patent/DK1663183T3/da active
- 2004-08-23 DK DK10181268.3T patent/DK2258346T3/da active
- 2004-08-23 PT PT04816820T patent/PT1663183E/pt unknown
- 2004-08-23 EA EA200600473A patent/EA011924B1/ru not_active IP Right Cessation
- 2004-08-23 ES ES10181268.3T patent/ES2653762T3/es not_active Expired - Lifetime
- 2004-08-23 KR KR1020147007592A patent/KR101563222B1/ko active IP Right Grant
- 2004-08-23 SG SG10201507902UA patent/SG10201507902UA/en unknown
- 2004-08-23 DK DK15169378.5T patent/DK2942051T3/da active
- 2004-08-23 PT PT101812501T patent/PT2258344E/pt unknown
- 2004-08-23 UA UAA200603276A patent/UA85564C2/ru unknown
- 2004-08-23 EP EP04816820A patent/EP1663183B9/en not_active Revoked
- 2004-08-23 CN CN200480024748XA patent/CN1901884B/zh not_active Ceased
- 2004-08-23 ME MEP-2008-176A patent/ME00130B/me unknown
- 2004-08-23 PL PL10181264T patent/PL2258345T3/pl unknown
- 2004-08-23 SI SI200432412T patent/SI2258346T1/sl unknown
- 2004-08-23 MX MX2010013145A patent/MX358033B/es unknown
- 2004-08-23 EP EP17210362.4A patent/EP3354261A1/en not_active Withdrawn
- 2004-08-23 HU HUE15169378A patent/HUE038792T2/hu unknown
- 2004-08-27 TW TW093125927A patent/TWI342221B/zh active
-
2006
- 2006-02-23 CR CR8256A patent/CR8256A/es unknown
- 2006-02-24 EC EC2006006397A patent/ECSP066397A/es unknown
- 2006-02-26 IL IL173939A patent/IL173939A/en active IP Right Grant
- 2006-02-27 ZA ZA200601718A patent/ZA200601718B/xx unknown
- 2006-03-24 NO NO20061342A patent/NO330282B1/no not_active Application Discontinuation
- 2006-12-06 HK HK06113444.9A patent/HK1094766A1/xx not_active IP Right Cessation
-
2007
- 2007-12-19 AU AU2007249115A patent/AU2007249115B2/en not_active Revoked
-
2008
- 2008-02-08 ZA ZA2008/01361A patent/ZA200801361B/en unknown
-
2010
- 2010-03-15 NO NO20100367A patent/NO334418B1/no not_active Application Discontinuation
- 2010-07-27 IL IL207260A patent/IL207260A/en active IP Right Grant
- 2010-11-01 AU AU2010238573A patent/AU2010238573B2/en not_active Revoked
- 2010-12-30 HK HK10112283.9A patent/HK1145969A1/xx not_active IP Right Cessation
-
2011
- 2011-02-18 JP JP2011032972A patent/JP5498411B2/ja not_active Expired - Lifetime
- 2011-07-06 JP JP2011149721A patent/JP5395125B2/ja not_active Expired - Lifetime
- 2011-07-25 HR HR20110555T patent/HRP20110555T1/hr unknown
- 2011-09-22 CY CY20111100923T patent/CY1111981T1/el unknown
-
2012
- 2012-12-21 CR CR20120662A patent/CR20120662A/es unknown
- 2012-12-21 CR CR20120661A patent/CR20120661A/es unknown
-
2013
- 2013-02-01 CY CY20131100093T patent/CY1113596T1/el unknown
- 2013-08-13 JP JP2013168001A patent/JP5903413B2/ja not_active Expired - Lifetime
- 2013-12-27 NO NO20131743A patent/NO335326B1/no not_active Application Discontinuation
-
2015
- 2015-12-04 JP JP2015237449A patent/JP2016094433A/ja not_active Withdrawn
-
2016
- 2016-05-10 HK HK16105307.9A patent/HK1217298A1/zh not_active IP Right Cessation
- 2016-12-19 CY CY20161101315T patent/CY1118505T1/el unknown
-
2017
- 2017-09-11 JP JP2017173733A patent/JP2018035163A/ja active Pending
- 2017-09-18 IL IL254581A patent/IL254581A0/en unknown
- 2017-11-03 CY CY20171101155T patent/CY1119651T1/el unknown
-
2018
- 2018-04-17 CY CY20181100407T patent/CY1120138T1/el unknown
- 2018-12-19 HK HK18116294.9A patent/HK1257502A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2942051T3 (da) | Fast farmaceutisk doseringsform der omfatter en fast dispersion af hiv-protease-inhibitor | |
US8399015B2 (en) | Solid pharmaceutical dosage form | |
AU2013201423B2 (en) | Solid pharmaceutical dosage form |